查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840823

CRISPR和Cas基因市場按應用、最終用戶、Cas類型、遞送方法和技術分類－2025-2032年全球預測

CRISPR & Cas Genes Market by Application, End User, Cas Type, Delivery Method, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CRISPR 和 Cas 基因市場將成長至 503.6 億美元，複合年成長率為 33.32%。

關鍵市場統計數據
基準年 2024 50.4億美元
預計年份：2025年 67.4億美元
預測年份 2032 503.6億美元
複合年成長率 (%) 33.32%

CRISPR和Cas基因演化的簡明框架以及在研究、轉化和商業功能方面進行策略合作的必要性

CRISPR及其相關的Cas基因系統已從實驗室工具迅速發展成為支撐現代基因編輯、診斷和治療設計的基礎平台。本文概述了CRISPR-Cas的技術發展歷程，闡述了其從基礎研究到應用流程的轉變，以及正在重塑轉化時間表的整合趨勢，包括遞送創新、多重編輯策略和診斷整合。在此基礎上，本文解釋了生物技術、生物製藥、委外研發機構和學術中心的領導者為何必須使其研究策略與新興平台的能力保持一致。

隨著該領域的日趨成熟，研究重點正從概念驗證性編輯轉向可重複、可擴展且符合監管要求的工作流程。新型Cas變體、改進的遞送方式以及配套的診斷讀數降低了臨床應用的門檻，同時也加劇了團隊必須應對的技術和商業性複雜性。本導言深入剖析了不斷變化的市場格局、考慮價格因素的供應模式、市場細分資訊以及區域性動態，旨在幫助科研、監管和商業領域的領導者做出明智的營運決策。

分子發現、遞送工程、診斷融合和監管成熟如何重塑研發路徑和策略重點

CRISPR和Cas系統的研究模式正因分子發現、遞送工程以及與診斷和計算生物學的跨學科整合等方面的同步進展而發生變革。新型Cas效應蛋白和工程突變體的發現正在拓展分子工具箱，使以往難以觸及的新標靶類型和編輯模式成為可能。同時，從非病毒奈米顆粒到改良的病毒載體和電穿孔方案等遞送技術的創新，使得對編輯活性進行時空控制成為可能。

此外，診斷技術正與基因編輯平台融合，形成閉合迴路工作流程，將檢測、分層和治療更緊密地整合在一起。這種轉變正在加速精準感染疾病診斷、照護現場基因篩檢和原位治療監測等應用情境的發展。法規環境也在日趨成熟，各機構發布了關於人類體細胞基因組編輯和診斷的指導意見，強調安全性、可追溯性和可重複性。因此，各機構正從單一資產計劃轉向以平台為導向的策略，這些策略以可擴展的生產、標準化的品質體係以及在交付、分析和臨床營運方面的夥伴關係為核心。這些因素共同作用，正在改變整個生態系統中專案的規劃、資金籌措和執行方式。

了解關稅帶來的供應鏈和採購壓力將如何迫使 CRISPR 專案實現供應多元化、考慮本地化生產以及製定應對策略。

關稅的徵收會改變供應鏈、採購成本以及實驗室和生產設施中設備和試劑的供應。就 CRISPR 和 Cas 系統而言，關鍵投入包括專用酵素和試劑、用於細胞操作和定序的精密設備，以及用於生產遞送載體的組件，例如脂質奈米顆粒化學品和病毒載體生產耗材。當關稅主導的成本壓力改變這些投入的經濟效益時，各組織會優先考慮供應的連續性、尋找合格的替代供應商，或將部分供應鏈本地化，以確保專案按時完成。

在營運方面，企業領導者獎勵重新評估庫存策略，投資於冗餘或地理分散的供應商，並加快供應商資格認證通訊協定。對於轉化醫學計畫而言，關鍵物資的延遲或供應不穩定可能導致臨床前研究週期延長和臨床試驗延期，從而錯失研發管線中的機會。貿易政策摩擦也會影響細胞處理和高通量定序平台等高價值資本設備的策略採購決策，促使企業重新談判服務等級協定或尋求翻新或國產替代方案。總之，關稅的影響不僅體現在直接的成本壓力上，也將成為研發和生產營運中供應彈性、在地化生產和供應商多元化的策略促進因素。

將應用、最終用戶、廢棄物類型、供應鏈和技術路徑連結起來的多維度細分智慧，可指導投資和營運選擇。

精細化的細分視角為轉換和商業性路徑的優先排序提供了切實可行的依據。基於應用領域，研究團隊和商業策略師應區分農業生物技術、動物模型開發、診斷、基因編輯和基因治療的投資，並認知到診斷可進一步細分為疾病檢測和基因篩檢，基因編輯可細分為研究和治療應用。這種應用領域的層級分類凸顯了監管複雜性、報銷途徑和見效時間的顯著差異。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 鹼基編輯技術的進步正在推動精準基因治療，並減少脫靶效應。
  • CRISPR基因編輯平台在治療遺傳疾病的商業性化應用已進入臨床試驗階段。
  • 新興的體內遞送載體最佳化了CRISPR Cas蛋白複合物，使其具有目標組織特異性。
  • 生技公司與合約研究組織建立策略夥伴關係關係，以加速 CRISPR篩檢服務
  • 正在不斷改進的法規結構旨在解決人類生殖細胞基因編輯試驗中的倫理問題

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. CRISPR和Cas基因市場按應用領域分類

  • 農業生物技術
  • 動物模型開發
  • 診斷
    • 疾病檢測
    • 基因檢測
  • 基因編輯
    • 研究用途
    • 治療用途
  • 基因治療

9. 按最終使用者分類的 CRISPR 和 Cas 基因市場

  • 生技公司
    • 已成立的公司
    • Start-Ups
  • 合約研究機構
    • 臨床服務
    • 臨床前服務
  • 製藥公司
    • 生物製藥公司
    • 大型製藥公司
  • 研究所

10. CRISPR 和 Cas 基因市場（按 CAS 類型分類）

  • Cas12
  • Cas13
  • Cas14
  • Cas9

11. CRISPR 和 Cas 基因市場按遞送方式分類

  • 電穿孔
  • 脂質體轉染
  • 顯微注射
  • 奈米顆粒遞送
    • 脂質奈米顆粒
    • 聚合物奈米粒子
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒

12. CRISPR 和 Cas 基因市場（按技術分類）

  • 體外
    • 細胞株工程
    • 初代細胞的修飾
  • 體內
    • 臨床試驗
    • 臨床前模型

13. CRISPR和Cas基因市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 CRISPR和Cas基因市場（按群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國 CRISPR 和 Cas 基因市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • PerkinElmer, Inc.
    • GenScript Biotech Corporation
    • Bio-Rad Laboratories, Inc.
    • Synthego Corporation
Product Code: MRR-5642D503D83C

The CRISPR & Cas Genes Market is projected to grow by USD 50.36 billion at a CAGR of 33.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.04 billion
Estimated Year [2025] USD 6.74 billion
Forecast Year [2032] USD 50.36 billion
CAGR (%) 33.32%

A concise framing of CRISPR and Cas gene evolution and the imperative for strategic alignment across research, translational, and commercialization functions

CRISPR and its associated Cas gene systems have rapidly evolved from a laboratory tool into a foundational platform that underpins modern gene editing, diagnostics, and therapeutic design. This introduction synthesizes the technical lineage of CRISPR-Cas, its transition from basic research into applied pipelines, and the converging trends-such as delivery innovation, multiplex editing strategies, and diagnostic integration-that are reshaping translational timelines. In doing so, it frames why organizational leaders across biotechnology, biopharma, contract research organizations, and academic centers must align research strategy with emergent platform capabilities.

As the field matures, emphasis is shifting from proof-of-concept edits to reproducible, scalable, and regulatory-compliant workflows. Novel Cas variants, improved delivery modalities, and paired diagnostic-readouts have collectively lowered barriers to clinical translation while simultaneously amplifying the technical and commercial complexity teams must navigate. This introduction therefore sets the scene for deeper sections that address landscape shifts, tariff-driven supply considerations, segmentation intelligence, and region-specific dynamics, all of which inform operational choices for science, regulatory, and commercial leaders.

How molecular discovery, delivery engineering, diagnostic convergence, and regulatory maturation are collectively reshaping development pathways and strategic priorities

The landscape for CRISPR and Cas systems is undergoing transformative shifts driven by parallel advances in molecular discovery, delivery engineering, and cross-disciplinary integration with diagnostics and computational biology. Discovery of alternative Cas effectors and engineered variants is expanding the molecular toolbox, enabling new target classes and editing modalities that were previously inaccessible. Concomitantly, delivery innovations-ranging from nonviral nanoparticles to refined viral vectors and electroporation protocols-are enabling spatial and temporal control over editing activity, which in turn reduces off-target risk and enhances therapeutic index.

Translationally, diagnostics are converging with editing platforms to create closed-loop workflows where detection, stratification, and treatment are more tightly coupled. This shift is accelerating use cases in precision infectious disease diagnostics, point-of-care genetic screening, and in situ therapeutic monitoring. The regulatory environment is also maturing, with agencies publishing guidance on human somatic genome editing and diagnostics that emphasize safety, traceability, and reproducibility. As a result, organizations are moving from single-asset projects to platform-oriented strategies that center on scalable manufacturing, standardized quality systems, and partnerships across delivery, analytics, and clinical operations. Together, these dynamics are changing how programs are designed, funded, and executed across the ecosystem.

Understanding how tariff-driven supply chain and procurement pressures compel supply diversification, local manufacturing considerations, and resilience strategies for CRISPR programs

The introduction of tariffs can alter supply chains, procurement costs, and the cadence of equipment and reagent availability for laboratories and manufacturing facilities. In the context of CRISPR and Cas systems, key inputs include specialized enzymes and reagents, precision instrumentation for cell manipulation and sequencing, and components for manufacturing delivery modalities such as lipid nanoparticle chemistries and viral vector production consumables. When tariff-driven cost pressure changes the economics of these inputs, organizations respond by prioritizing supply continuity, qualifying alternative suppliers, or localizing portions of their supply base to preserve program timelines.

Operationally, leaders are incentivized to reassess inventory strategies, invest in redundant or regionally distributed suppliers, and accelerate vendor qualification protocols. For translational programs, any delay or variance in critical supplies can cascade into longer preclinical timelines or deferred clinical activities, creating opportunity costs for pipelines. Trade policy friction also influences strategic sourcing decisions for high-value capital equipment such as cell processing and high-throughput sequencing platforms, prompting organizations to renegotiate service-level agreements or explore refurbished and domestically produced alternatives. In sum, tariff impacts manifest not only as direct cost pressures but as strategic drivers of supply resilience, local manufacturing consideration, and supplier diversification across R&D and manufacturing operations.

Multidimensional segmentation intelligence linking application, end user, Cas type, delivery modality, and technology pathways to guide investment and operational choices

A granular segmentation view provides practical levers for prioritization across translational and commercial pathways. Based on Application, research teams and commercial strategists must differentiate investments across Agricultural Biotechnology, Animal Model Development, Diagnostics, Gene Editing, and Gene Therapy, recognizing that Diagnostics is further divided into Disease Detection and Genetic Screening while Gene Editing splits into Research Applications and Therapeutic Applications. This layered application segmentation clarifies where regulatory complexity, reimbursement pathways, and time-to-impact differ markedly.

Based on End User, the ecosystem dynamics change depending on the buyer and operator: Biotechnology Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes each bring different procurement rhythms and risk tolerances. Within this, Biotechnology Companies can be viewed through the lens of Established Firms versus Startups; Contract Research Organizations separate into Clinical Services and Preclinical Services; and Pharmaceutical Companies include both Biopharma Firms and Large Pharma. These distinctions matter for partner selection, contracting models, and commercialization timelines.

Based on Cas Type, applications track to molecular capability: Cas12, Cas13, Cas14, and Cas9 each have distinct biochemical properties and target class compatibilities, which influence assay design, therapeutic targeting, and IP considerations. Based on Delivery Method, practical trade-offs exist among Electroporation, Liposome Transfection, Microinjection, Nanoparticle Delivery, and Viral Vector, with Nanoparticle Delivery subdividing into Lipid Nanoparticles and Polymer Nanoparticles and Viral Vector further subdividing into Adeno Associated Virus, Adenovirus, and Lentivirus. Each delivery option requires different manufacturing capabilities, regulatory dossiers, and safety-monitoring frameworks.

Finally, Based on Technology, programs diverge along Ex Vivo and In Vivo pathways. Ex Vivo work is refined into Cell Line Engineering and Primary Cell Modification, which often emphasizes process control and closed-system manufacturing, while In Vivo approaches encompass Clinical Trials and Preclinical Models and prioritize biodistribution, immunogenicity, and delivery optimization. Together, these segmentation layers create a multidimensional view that helps leaders prioritize where to allocate capital, how to structure partnerships, and which operational capabilities to develop internally.

Regional development, regulatory variation, and investment dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and operational strategy

Regional dynamics shape how CRISPR and Cas gene technologies are developed, funded, and adopted, and understanding geographic nuances helps allocate commercial and operational resources effectively. In the Americas, public and private investment ecosystems are robust and often support high-risk translational projects, with strong venture capital activity and major clinical development centers that accelerate first-in-human studies. This region tends to lead in platform startups and partnering transactions that bridge academic innovation and commercial scaling, while also facing concentrated regulatory scrutiny and payer dynamics that influence clinical development strategies.

Europe, Middle East & Africa present a heterogeneous regulatory and funding landscape where collaborative research networks, strong academic hubs, and strategic national initiatives coexist with varied reimbursement systems and approval timelines. Regional centers of excellence emphasize translational rigor and early patient engagement, and cross-border collaborations are common to access patient cohorts and diverse expertise. Concurrently, nations within the region prioritize different technology pathways based on local public health needs and industrial policy.

Asia-Pacific exhibits rapid adoption driven by significant public R&D investment, expanding domestic biopharma capability, and a growing manufacturing base for biologics and delivery systems. Several markets are actively building clinical trial capacity and local regulatory clarity to attract global development programs. As a result, Asia-Pacific is increasingly important for scaling manufacturing, accessing diverse patient populations, and sourcing specialized reagents and components, making it an essential region for global operational planning.

How platform breadth, delivery capability, clinical execution, manufacturing scale, and strategic partnerships define competitive advantage and partnership opportunities

Company strategies in the CRISPR and Cas gene ecosystem are converging around a set of differentiators: platform breadth, delivery expertise, clinical execution capability, manufacturing scale, and strategic partnerships. Platform breadth is valuable for firms that aim to address multiple therapeutic areas or diagnostic applications, because it enables asset-level diversification and cross-program learning. Delivery expertise has become a critical competitive moat; organizations that can reliably deliver editing machinery with favorable safety profiles command a higher strategic premium and greater ability to partner with large clinical developers.

Clinical execution and regulatory navigation distinguish companies that successfully transition from discovery-stage programs to late-stage development. Firms investing early in manufacturing and quality systems shorten the timeline from clinical proof-of-concept to commercial readiness. Strategic partnerships, whether they are co-development agreements, technology licensing, or manufacturing collaborations, are central to scale-up strategies and risk-sharing. Across the ecosystem, successful companies combine deep technical expertise with operational dexterity, aligning R&D pipelines to pragmatic commercialization routes and forming partnerships that address gaps in delivery, analytics, and regulatory affairs.

Targeted operational and partnership actions to de-risk pipelines, scale manufacturing modularity, and accelerate regulated translation of CRISPR and Cas gene initiatives

Industry leaders should adopt a set of actionable priorities that translate insight into measurable progress. First, prioritize supplier and delivery redundancy by qualifying alternative reagent and equipment suppliers, and by validating multiple delivery approaches to de-risk program timelines. Second, invest in modular manufacturing and quality systems that can be repurposed across ex vivo and in vivo programs to maximize capital efficiency while meeting evolving regulatory expectations. Third, align early regulatory engagement with robust safety and monitoring plans to streamline translational pathways and reduce later-stage attrition.

In parallel, pursue strategic collaborations that complement internal capabilities: partner with specialized CDMOs and delivery technology providers to accelerate manufacturing scale, and form data partnerships to enhance diagnostic and stratification strategies. Build internal capabilities in analytical characterization and bioinformatics to optimize editing specificity and to support regulatory dossiers. Finally, develop market-access playbooks that integrate diagnostic companion strategies, payer engagement, and clear value narratives to support commercialization decisions. These actions create a defensible, pragmatic path from innovation to sustained clinical and commercial impact.

A mixed-methods research approach combining primary interviews, literature synthesis, regulatory analysis, and scenario testing to validate strategic conclusions and assumptions

The research methodology underpinning this analysis blends primary and secondary intelligence with rigorous synthesis to ensure actionable reliability. Primary inputs include structured interviews with technical leaders across biotech, contract research organizations, pharmaceutical development teams, and academic investigators, supplemented by direct input from manufacturing and regulatory professionals. Secondary inputs incorporate peer-reviewed literature, publicly available regulatory guidance, patent analysis, and clinical trial registry data to triangulate program trajectories and technology adoption patterns.

Analytical approaches applied include technology readiness assessments, supply chain stress-testing, and scenario planning that incorporates policy and trade variables. Where appropriate, cross-validation was used to reconcile divergent perspectives, ensuring conclusions reflect consensus where it exists and clearly flag areas of uncertainty. This mixed-method approach provides executives with a robust base of evidence to inform strategy, while also highlighting critical assumptions and sensitivity points that merit ongoing monitoring.

Synthesis of platform maturation, supply resilience, delivery innovation, and partnership imperatives to convert CRISPR science into durable clinical and commercial outcomes

In conclusion, CRISPR and Cas gene systems are transitioning from compartmentalized laboratory methods to integrated platforms that span diagnostics, therapeutics, and agriculture. Key inflection points include maturation of delivery technologies, the emergence of multiple Cas effectors with complementary capabilities, and an evolving regulatory environment that emphasizes reproducibility and safety. These dynamics create both opportunity and complexity: organizations that invest in diversified delivery strategies, resilient supply chains, and targeted partnerships will be best positioned to capture translational value.

Looking ahead, executives should balance near-term operational resilience with longer-term platform investments. Prioritizing modular manufacturing, regulatory foresight, and cross-sector partnerships will enable organizations to convert technical innovation into clinical and commercial outcomes. Sustained progress will depend on disciplined execution, transparent data practices, and continued investment in delivery and analytics capabilities that together reduce technical risk and improve patient and market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in base editing technologies driving precision gene therapies with reduced off-target effects
  • 5.2. Commercial adoption of CRISPR prime editing platforms for treatment of genetic disorders in clinical pipelines
  • 5.3. Emergence of in vivo delivery vehicles optimizing CRISPR Cas protein complexes for targeted tissue specificity
  • 5.4. Strategic partnerships between biotech firms and contract research organizations to accelerate CRISPR screening services
  • 5.5. Regulatory frameworks evolving to address ethical considerations around human germline gene editing trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR & Cas Genes Market, by Application

  • 8.1. Agricultural Biotechnology
  • 8.2. Animal Model Development
  • 8.3. Diagnostics
    • 8.3.1. Disease Detection
    • 8.3.2. Genetic Screening
  • 8.4. Gene Editing
    • 8.4.1. Research Applications
    • 8.4.2. Therapeutic Applications
  • 8.5. Gene Therapy

9. CRISPR & Cas Genes Market, by End User

  • 9.1. Biotechnology Companies
    • 9.1.1. Established Firms
    • 9.1.2. Startups
  • 9.2. Contract Research Organizations
    • 9.2.1. Clinical Services
    • 9.2.2. Preclinical Services
  • 9.3. Pharmaceutical Companies
    • 9.3.1. Biopharma Firms
    • 9.3.2. Large Pharma
  • 9.4. Research Institutes

10. CRISPR & Cas Genes Market, by Cas Type

  • 10.1. Cas12
  • 10.2. Cas13
  • 10.3. Cas14
  • 10.4. Cas9

11. CRISPR & Cas Genes Market, by Delivery Method

  • 11.1. Electroporation
  • 11.2. Liposome Transfection
  • 11.3. Microinjection
  • 11.4. Nanoparticle Delivery
    • 11.4.1. Lipid Nanoparticles
    • 11.4.2. Polymer Nanoparticles
  • 11.5. Viral Vector
    • 11.5.1. Adeno Associated Virus
    • 11.5.2. Adenovirus
    • 11.5.3. Lentivirus

12. CRISPR & Cas Genes Market, by Technology

  • 12.1. Ex Vivo
    • 12.1.1. Cell Line Engineering
    • 12.1.2. Primary Cell Modification
  • 12.2. In Vivo
    • 12.2.1. Clinical Trials
    • 12.2.2. Preclinical Models

13. CRISPR & Cas Genes Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. CRISPR & Cas Genes Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. CRISPR & Cas Genes Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Agilent Technologies, Inc.
    • 16.3.6. Illumina, Inc.
    • 16.3.7. PerkinElmer, Inc.
    • 16.3.8. GenScript Biotech Corporation
    • 16.3.9. Bio-Rad Laboratories, Inc.
    • 16.3.10. Synthego Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRISPR & CAS GENES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA CRI